Correspondence 0001193125-25-065485 from Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc.
Date: March 27, 2025 · CIK: 0001826457 · Accession: 0001193125-25-065485
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285942
Letter
Re: Monte Rosa Therapeutics, Inc.: Registration Statement on Form S-3 filed March 20, 2025 (File No. 333-285942) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Monte Rosa Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to March 31, 2025, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Robert Puopolo, Esq. of Goodwin Procter LLP at (617) 570-1393.
Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, MA 02118 March 27, 2025 Via EDGAR Transmission Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes
Sincerely,
MONTE ROSA THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, MA 02118 March 27, 2025 Via EDGAR Transmission Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Monte Rosa Therapeutics, Inc.: Registration Statement on Form S-3 filed March 20, 2025 (File No. 333-285942) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Monte Rosa Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to March 31, 2025, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Robert Puopolo, Esq. of Goodwin Procter LLP at (617) 570-1393. Sincerely, MONTE ROSA THERAPEUTICS, INC. /s/ Markus Warmuth Markus Warmuth, M.D. President and Chief Executive Officer cc: Philip Nickson, Esq., Monte Rosa Therapeutics, Inc. Robert Puopolo, Esq., Goodwin Procter LLP Kristen McCarthy, Esq., Goodwin Procter LLP